enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.…
enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium
enVVeno Medical (NASDAQ: NVNO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 33 employees.
The shares were at 5.250 USD on 20 November 2026, down 77.1% over 52 weeks. Its 52-week range is 5.220 USD to 24.50 USD, and it trades at the bottom of that range.
Its market capitalisation is 3.65M USD.
enVVeno Medical reports return on equity of -71.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 18.06M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.